コーパス検索結果 (１語後でソート)
通し番号をクリックするとPubMedの該当ページを表示します
1 rom an in-house screening library of a major pharmaceutical company.
2 een demonstrated on the example of a Spanish pharmaceutical company.
3 combinations through collaborations with 18 pharmaceutical companies.
4 s of $100 or more were made to physicians by pharmaceutical companies.
5 f intensive research both in academia and in pharmaceutical companies.
6 cientific meetings and contacted experts and pharmaceutical companies.
7 tracts; and contacting authors, experts, and pharmaceutical companies.
8 current perception at the majority of large pharmaceutical companies.
9 (NGDO) support, and donations of drugs from pharmaceutical companies.
10 CR5 antagonists identified by five different pharmaceutical companies.
11 tself has stimulated the interest of several pharmaceutical companies.
12 published trials, contacting researchers and pharmaceutical companies.
13 ns to the US Food and Drug Administration by pharmaceutical companies.
14 to patients, managed care organizations and pharmaceutical companies.
15 d academic scientists hoping to partner with pharmaceutical companies.
16 tor ligands from discovery programs in major pharmaceutical companies.
17 en intensely pursued both in academia and in pharmaceutical companies.
18 eved from ClinicalTrials.gov and websites of pharmaceutical companies.
19 data from completed studies sponsored by 13 pharmaceutical companies.
20 egard they have attracted much interest from pharmaceutical companies.
21 attention from the scientific community and pharmaceutical companies.
22 arisons of two drugs in studies sponsored by pharmaceutical companies.
23 t, and protons were developed by a number of pharmaceutical companies.
24 therapeutics under investigation in various pharmaceutical companies.
25 nd contact with study authors and device and pharmaceutical companies.
26 cal trials were systematically identified by pharmaceutical companies.
27 disclosure of payments made to physicians by pharmaceutical companies.
29 er the federal government (75/117; 64.1%) or pharmaceutical companies (46/117; 39.3%) to perform gene
30 ntibacterial research shifts away from large pharmaceutical companies, a wave of biotechnology compan
33 rt interfering RNAs (siRNA), researchers and pharmaceutical companies alike have devoted immense time
35 rnational collaboration of academic centres, pharmaceutical companies and a private foundation, to di
37 analysis (MMPA), we combined data from three pharmaceutical companies and generated ADMET rules, avoi
39 ed HAE expert physicians, representatives of pharmaceutical companies and representatives of HAE pati
40 basis for study protocol discussions between pharmaceutical companies and the FDA in advancing the de
41 commitment to patient care and the desire of pharmaceutical companies and their representatives to se
42 ermittent dosing or between trials funded by pharmaceutical companies and those independently funded.
43 Here I describe how partnering works in a pharmaceutical company and offer advice on how to make a
44 dentified on MEDLINE, inquiry of experts and pharmaceutical companies, and data presented at recent n
45 s, development of commercial vaccines by the pharmaceutical companies, and participation of many pati
46 gencies, policy-setting bodies, governments, pharmaceutical companies, and philanthropic organization
47 and Current Content, inquiry of experts and pharmaceutical companies, and preliminary data presented
48 lished evidence was from trials sponsored by pharmaceutical companies, and publication bias may have
49 medical and scientific databases, approached pharmaceutical companies, and reviewed citations of rele
50 ves from the NHLBI, patient advocacy groups, pharmaceutical companies, and the U.S. Food and Drug Adm
51 a research project with representatives of a pharmaceutical company, and they propose a model for tea
54 nies, federal payers, medical societies, and pharmaceutical companies are increasingly utilizing heal
59 cs, why academic researchers and biotech and pharmaceutical companies are so excited, and what the ob
60 environment, and insufficient investments by pharmaceutical companies are some of the clear reasons b
63 r persons ineligible for such subsidies, and pharmaceutical company assistance may be a better altern
66 tion participation, positive phase II trial, pharmaceutical company-based trials, and shorter time pe
68 ity of the C-CASA ratings and agreement with pharmaceutical company classification were estimated.
69 etween a voluntary health organization and a pharmaceutical company, complemented by academic investi
70 compounded by the fact that there are fewer pharmaceutical companies conducting research to discover
71 second shows how they restricted to whom the pharmaceutical company could market its transdermal nico
72 ion of brain striatal signaling, and several pharmaceutical companies currently investigate PDE10A in
74 ents were not released to the public because pharmaceutical companies designated them as trade secret
78 a pharmacological perspective, with several pharmaceutical companies developing NR2B subtype-selecti
79 , dexketoprofen, deflazacort) handled by the pharmaceutical company employees in the making of tablet
83 to progress and discourages researchers and pharmaceutical companies from investing resources to dev
84 e statements for accuracy, determine whether pharmaceutical companies from which the authors received
85 from newspaper and online sources about all pharmaceutical company-funded medication studies publish
86 g on medication studies often fail to report pharmaceutical company funding and frequently refer to m
87 tors who indicate that their articles report pharmaceutical company funding; the percentage of editor
88 tions of safe and effective drugs by several pharmaceutical companies, funds for delivering these don
92 opulations that might have adverse outcomes, pharmaceutical companies have been reluctant to use a st
95 g pocket on the protein surface, and several pharmaceutical companies have developed compounds and pe
98 greatly expanded as clinical researchers and pharmaceutical companies have focused their efforts on d
99 quent dissolutions of in-house facilities by pharmaceutical companies have had media channels pronoun
103 influence of physicians' practice patterns, pharmaceutical companies, health maintenance organizatio
106 ntagonists is under investigation by several pharmaceutical companies in an effort to identify novel
110 considerable interest from both academia and pharmaceutical companies in the discovery and developmen
115 undertake the task of picking up where large pharmaceutical companies left off have failed to survive
118 nterest in antibacterial discovery and large pharmaceutical companies may look to these as a source o
121 even in some brand name products from major pharmaceutical companies not of natural oyster shell der
122 ird case, we show how subsidiary tobacco and pharmaceutical companies of a parent company collaborate
123 examined industry-wide trends in spending by pharmaceutical companies on direct-to-consumer advertisi
124 edication research has received funding from pharmaceutical companies or how frequently news articles
128 available P2RX7 knock-out mice generated by pharmaceutical companies possess certain splice variants
129 urred without assistance and with the use of pharmaceutical company programs for the cohort and FPL c
130 re population without prescription coverage, pharmaceutical company programs offered considerable sav
131 greement was observed between the C-CASA and pharmaceutical company ratings, with the C-CASA reportin
135 The effects of health economics research on pharmaceutical company revenue make drug investigations
136 that drug, and, under the current system, a pharmaceutical company's appraisal of SADRs may be influ
137 hat have been reported by Merck and Shionogi pharmaceutical companies, served as model ADK leads.
138 ntre study independent from the influence of pharmaceutical companies should be commissioned to compa
140 results were not significantly different in pharmaceutical company-sponsored (6/20 [30%]) vs nonprof
142 vidual studies, these findings indicate that pharmaceutical company sponsorship of economic analyses
143 eeding trials, clinical studies conducted by pharmaceutical companies that are designed to seem as if
144 s has been referred to as the "graveyard for pharmaceutical companies." That is now set to change, as
145 bridging the gap between academia and large pharmaceutical companies, the biotech firms have been ef
146 atient advocacy groups, medical oncologists, pharmaceutical companies, the US Food and Drug Administr
147 y or had at least 1 author affiliated with a pharmaceutical company; the remaining trials did not rep
148 ith academia, health-care professionals, and pharmaceutical companies, this initiative aims to streng
149 e recent low annual output of new drugs from pharmaceutical companies, this review will provide a tim
150 prove drug development, as it would pressure pharmaceutical companies to become more innovative and a
151 ractions in their prescriptions and will aid pharmaceutical companies to design large-scale clinical
152 is driven by four factors: the commitment of pharmaceutical companies to provide free drugs; the scal
153 One shows how tobacco companies pressured pharmaceutical companies to scale back their smoking ces
154 erial (or antibiotic) agents from the larger pharmaceutical companies to the entrepreneur-like small
157 d lowest when consent was not obtained and a pharmaceutical company used data for marketing (weighted
158 The percentage of successful trials from pharmaceutical companies was significantly higher compar
159 rmidable drug development resources of large pharmaceutical companies were deployed into Phase 3 tria
160 12 events originally labeled as suicidal by pharmaceutical companies were eliminated, which resulted
162 tion) that were not originally identified by pharmaceutical companies were identified in the C-CASA,
164 currently under investigation by a number of pharmaceutical companies with only a few reaching early
165 cals, and pharmaceuticals; all international pharmaceutical companies with sales volumes similar to t
166 ides the promise of increased efficiency for pharmaceutical companies, with higher confidence in the
167 on of methods for distinguishing biotech and pharmaceutical companies yields a dynamic, more accurate
WebLSDに未収録の専門用語（用法）は "新規対訳" から投稿できます。